Vibalogics: Tom Hochuli
Vibalogics has appointed Tom Hochuli as Chief Executive Officer. Hochuli will be responsible for accelerating the German CDMO’s expansion plans in the US and globally: with its sights set on a late phase and commercial virus manufacturing facility on the East Coast of the US.
Vibalogics specializes in the manufacturing of oncolytic viruses, viral vector vaccines and viral vectors offering process development, manufacturing, testing and fill-finish services for early phase clinical trials from its 50,000 sq. ft. GMP certified facility in Cuxhaven, Germany. The company was acquired by private equity firm Ampersand Capital Partners last year.
Vibalogics has been selected by Janssen Pharmaceutical Companies, a Johnson & Johnson company, as one of its manufacturing partners for its COVID-19 vaccine candidate (which has just entered Phase 3 trials).
Hochuli has more than 25 years’ experience with CDMOs and large pharmaceutical companies; and was previously head of cell and gene therapy operations for Lonza Houston.
